317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision
The Readout Loud
00:00
Biotech VC Landscape: Challenges and Optimism
This chapter examines the annual rankings of biotech venture capital firms, detailing their struggles and recovery paths post-market downturn. It highlights signs of optimism including recent successes in acquisitions and fundraising, while comparing the biotech sector's resilience to that of other VC domains.
Transcript
Play full episode
